Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Key uncertainties include the human translational relevance of the gliopeptide system, the stability and bioavailability of TDN in humans, potential off-target CNS effects, and the consequences of chronically manipulating glial function. To continue investigating TDN and other ODN derivatives, the press release stated that a new biotech company called CoronationBio has licensed the intellectual property from Syracuse University and the University of Pennsylvania and plans to begin human trials in 2026 or 2027.
[1] Primarily, it stimulates insulin secretion from the pancreas when blood glucose levels are elevated, whilst simultaneously suppressing the release of glucagon, a hormone that raises blood sugar
Pipeline of new drugs and dosage forms
In clinical trials, which compared people randomly assigned to the active drug or a placebo, participants receiving semaglutide or tirzepatide lost 15% to 20% of their body weight on average
Some patients see changes earlier
This is particularly important for people with diabetes, as they are already at higher risk for kidney disease
